Amundi Arcutis Biotherapeutics, Inc. Transaction History

Amundi

$275 Billion
Q1 2025

A detailed history of Amundi transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Amundi holds 66 shares of ARQT stock, worth $889. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$889

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 15, 2025	BUY	$11.4 - $17.29 $752 - $1,141	66 New	66 $1,000
Q2 2022 Aug 15, 2022	BUY	$16.33 - $22.2 $77,959 - $105,982	4,774 New	4,774 $114,000

Others Institutions Holding ARQT

# of Institutions

252

Shares Held

126M

Call Options Held

605K

Put Options Held

170K

Suvretta Capital Management, LLC New York, NY

11.4M
Shares

$154 Million
7.82% of portfolio
Jennison Associates LLC

11.4M
Shares

$153 Million
0.13% of portfolio
Rubric Capital Management LP New York, NY

11M
Shares

$148 Million
4.91% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

8.79M
Shares

$118 Million
8.65% of portfolio
Black Rock Inc. New York, NY

8.62M
Shares

$116 Million
0.0% of portfolio

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $811M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account